CWS
NKTR icon

Confluence Wealth Services’s Nektar Therapeutics NKTR Stock Holding History

Confluence Wealth Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-779
Closed -$6.6K – 344
2023
Q4 		$6.6K Buy
+779
New +$5.9K ﹤0.01% 290

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Confluence Wealth Services's NKTR Position: Q1 2024 in Review

Confluence Wealth Services sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 779 shares — an estimated $6.6K sold.

Confluence Wealth Services first reported a position in NKTR in Q4 2023 and held it in 1 quarter. The position peaked at $6.6K in Q4 2023. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • Confluence Wealth Services reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Confluence Wealth Services sold 779 Nektar Therapeutics shares in Q1 2024, an estimated $6.6K.
  • Confluence Wealth Services first reported a position in Nektar Therapeutics in Q4 2023 and held it in 1 quarter.
  • Confluence Wealth Services's Nektar Therapeutics position peaked at $6.6K in Q4 2023.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Confluence Wealth Services's 13F filing for Q1 2024, filed 22 Apr 2024.